OHE https://validator.w3.org/feed/docs/rss2.html The value of fast diagnostics in time-critical infections A Dose of Economics Evaluating novel antimicrobials within EU joint clinical assessments  The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases The case for adopting a broader perspective on value in Health Technology Assessment Novel devices: optimising drug delivery in multiple myeloma A global landscape analysis of access to tumour-agnostic therapies  Capturing the lived experiences of informal care in acute leukemia The commercial case for investing in ALS Achieving Accelerated Patient Access to Cancer Care in Europe  Patient preferences for treatment in relapsed/refractory acute leukemia The value of cell and gene therapies to the UK economy Understanding the preferences of people with acute leukemia for different health outcomes The broader economic benefits of COVID-19 vaccination  Taking STRIDES: The value of diagnostics against AMR OHE’s submission to Belgium’s Committee on Health and Equal Opportunities argues value-based pricing delivers a ‘triple-win’ OHE to host the Health Economists’ Study Group Summer 2025 OHE responds to the King’s Speech and the proposed NHS Modernisation Bill When antibiotics stop working: the hidden crisis in plain sight Welcome to A Dose of Economics Most Favored Nation pricing: what it means for policy, patients and pharma  Contact us Stuart Carroll David McKinney Is the revised Congressional Budget Office model of new drug development fit for purpose? Can joint clinical assessment speed up access to medicines? Patrick Hopkinson OHE Graduate School Mid-year health check: policy, pricing & what’s coming OHE at the World Health Assembly 2026 The CBO Doesn’t Understand Investors Two numbers, one decision: making climate-health valuation usable across sectors Our team Does the New CBO Report Change Anything? Grainne Cremin Bradley Barker‑Jones OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking H.R. 3 is the Wrong Policy for the Wrong Problem CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation  Socio-Economic Value of Adult Immunisation Programmes Careers at OHE Around the World in HTAs: Canada – Autonomous yet Collaborative Around the World in HTAs: United States – Making HTA Great Again Valuing patient and carer time in HTA: equity and opportunity cost  Around The World in HTAs: The Netherlands – 5 Routes for New Tech Around the world in HTAs: Argentina – Long Road to Institutionalizing HTA OHE